Medicine from the group of peripherally acting µ-opioid receptor antagonists in the gastrointestinal tract, reducing the constipation effects of opioids without affecting their analgesic effect on the central nervous system, treatment of opioid-induced constipation, in the form of tablets.
Moventig is indicated for the treatment of:
opioid-induced constipation (OIC) in adult patients whose response to laxatives was insufficient.
Definition of insufficient response to laxatives:
during the two weeks preceding the use of naloxegol, reporting OIO symptoms of at least moderate intensity, which persisted even after taking a laxative for at least 4 days.
The obligation to establish a Publicly Accessible Professional Information Service (PAPIS)
result from Act No. 378/2007 Sb., O léčivech. Information on our products can be
found on the website of the State Institute for Drug Control (SÚKL) in the
Product information (SPC or PIL) is available by clicking on the product name and the
Summary of Product Characteristics (SPC) link.
The Publicly Accessible Professional Information Service (PAPIS) for Moventig
is operated by the marketing authorization holder - Pharma-Service International s.r.o., contact: